Treatments for multiple myeloma have grown a great deal. Newer drugs help people with this blood cancer live longer and enjoy a better quality of life.
Game-changing new drugs have been developed and introduced to Korea for treating blood cancers, including multiple myeloma. Still, an expert pointed out the nation’s gap in survival rates with adva...
Severance Hospital researchers have identified a promising method to rejuvenate the effectiveness of natural killer cells in combating multiple myeloma, a serious form of blood cancer. Multiple myeloma is characterized by the malignant transformation of plasma cells, which are crucial to the body's immune system. These cancerous cells produce an abnormal protein known as M-protein, leading to various complications such as fractures, infections, and kidney failure, thereby increasing susceptibili...
The Ministry of Food and Drug Safety (MFDS) said on Thursday that it has approved an orphan drug Elrexfio (elranatamab), imported by Pfizer Korea. The drug is indicated as monotherapy in adult patients with relapsed or refractory multiple myeloma who have received three or more prior therapies, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies. Elrexfio destroys multiple myeloma cancer cells in an immune response by targeting B-cell maturation antigen ...
After oncology experts reviewed arguments in favor of a surrogate endpoint to support multiple myeloma drug approvals, drug developers may soon have a new pathway in the R&D journey.
Many different types of drugs can be used to treat multiple myeloma. Learn more about them here.
New drugs have made it possible to live much longer with the disease, and some scientists even see a possible cure down the road.
Each year, CDER approves a wide range of new drugs and biological products.
On September 20, 2024, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). Full prescribing information for Sarclisa will be posted on Drugs@FDA. Efficacy was evaluated in IMROZ (NCT03319667), an open-label, randomized, active-controlled phase 3 trial in patients with newly diagnosed multiple m...
Abstract ; Background : Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies. Results : In total, 494 patients were randomly assigned to receive BVd (243 patients) or DVd (251 patients). At a median follow-up of 28.2 months (range, 0.1 to 40.0), median progression-free survival was 36.6 months (95% confidence interval [CI], 28.4 to not reached) i...